Completed Clinical Trials

An Open-label, Phase II Trial of ZD1839 (IRESSA) in Patients With Malignant Mesothelioma

By April 24, 2017 No Comments

Condition

Mesothelioma

Estimated Enrollment: 23

Age Group: 18 Years and older   (Adult, Senior)

Gender: All

Study Type: Interventional

Study Design Allocation: Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment

Study ID Numbers: 1839IL/0094

Study First Received: November 6, 2008

Last Updated: June 5, 2012

Estimated Primary Completion Date: April 2008

 

Primary Outcome Measures:

To assess the activity of ZD1839 in patients with malignant mesothelioma by estimating the objective response rate (CR and PR) at trial closure|To further characterize the safety profile of ZD1839 at a 250mg daily dose|To estimate PFS (progression free survival)|To estimate overall survival|To estimate duration of response

Sponsors and Collaborators:

AstraZeneca

Website Link: https://ClinicalTrials.gov/show/NCT00787410

Leave a Reply

Call Now